MG
PROK icon

Michael Gelband’s ProKidney PROK Stock Holding History

Michael Gelband’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-254,353
Closed -$455K – 1960
2026
Q1 		$455K Buy
254,353
+125,500
+97% +$266K ﹤0.01% 1216
2025
Q4 		$289K Buy
128,853
+23,924
+23% +$62.9K ﹤0.01% 1320
2025
Q3 		$254K Buy
104,929
+93,266
+800% +$248K ﹤0.01% 1337
2025
Q2 		$7K Buy
+11,663
New +$9.08K ﹤0.01% 1400
2023
Q2 		– Sell
-13,343
Closed -$151K – 2175
2023
Q1 		$151K Buy
+13,343
New +$142K ﹤0.01% 1603
2022
Q1 		– Sell
-50,000
Closed -$495K – 2580
2021
Q4 		$495K Hold
50,000
– – 0.01% 1420
2021
Q3 		$490K Hold
50,000
– – 0.01% 1410
2021
Q2 		$506K Buy
+50,000
New +$506K 0.01% 1397

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's PROK Position: Q2 2026 in Review

Michael Gelband sold out of ProKidney (PROK) in Q2 2026, closing a stake of 254,353 shares — an estimated $455K sold.

Michael Gelband first reported a position in PROK in Q2 2021 and held it in 8 quarters. The position peaked at $506K in Q2 2021. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • Michael Gelband reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 254,353 ProKidney shares in Q2 2026, an estimated $455K.
  • Michael Gelband first reported a position in ProKidney in Q2 2021 and held it in 8 quarters.
  • Michael Gelband's ProKidney position peaked at $506K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.